Cargando…
Fournier´s Gangrene Under Sodium-Glucose Cotransporter 2 Inhibitor Therapy as a Life-Threatening Adverse Event: A Case Report and Review of the Literature
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of oral antidiabetic drugs. The US FDA has recently published a new warning about the safety of SGLT2 inhibitor administration in type 2 diabetes mellitus patients. There is an emerging evidence of an increased risk for dev...
Autores principales: | Rodler, Severin, Weig, Thomas, Finkenzeller, Christa, Stief, Christian, Staehler, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825492/ https://www.ncbi.nlm.nih.gov/pubmed/31723537 http://dx.doi.org/10.7759/cureus.5778 |
Ejemplares similares
-
Isolated Penile Fournier's Gangrene: A Rare Case
por: Batmaz, Orkun, et al.
Publicado: (2020) -
Fournier’s Gangrene under Sodium–Glucose Cotransporter-2 Inhibitors Therapy in Gynecological Patients
por: Serrano Olave, Adriana, et al.
Publicado: (2022) -
A Rare but Life-Threatening Case of Fournier’s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin
por: Jahir, Tahmina, et al.
Publicado: (2022) -
Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
por: Yang, Jeff Yufeng, et al.
Publicado: (2020) -
Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
por: Hu, Yang, et al.
Publicado: (2020)